|
|
News Breaks | | | | October 2, 2012 | | 06:02 EDT |  | ASTX | Astex Pharmaceuticals announces initiation of SGI-110 Phase 2 trial
Astex Pharmaceuticals announced that it has initiated a Phase 2, open label, randomized, multi-center, controlled clinical trial, evaluating SGI-110 in combination with carboplatin in platinum-resistant recurrent ovarian cancer patients. Study SGI-110-02 will have two stages: a safety lead-in stage followed by a randomized, controlled, open-label stage. | |
|
News For ASTX From The Last 14 Days Check below for free stories on ASTX the last two weeks. |
|
|
| June 14, 2013 | | 06:02 EDT | | ASTX | Astex Pharmaceuticals announced updated clinical results of SGI-110
 Subscribe for More Information | |
|
|
|
|
|
|
